Skip to main content
Premium Trial:

Request an Annual Quote

Abbott, Pfizer Partner on Companion Dx for Cancer Drug

NEW YORK (GenomeWeb News) – Abbott yesterday said that it will partner with Pfizer on a molecular diagnostic test to screen non-small cell lung cancer tumors for the presence of gene rearrangements.

Pfizer is developing a drug that selectively targets cancer-causing genes implicated in the progress of many cancers, the firms said in a statement. For patients to be eligible to receive the drug candidate, a particular genetic translocation known to be present in NSCLC tumors and others cancers, but not in normal cells, must be identified in the tumor sample.

Abbott will develop a companion diagnostic test that will determine if a patient's genetic status makes them eligible for selection in future clinical trials of the compound, PF-02341066.

"Pfizer's novel compound for treating non-small cell lung cancer appears to be ideally suited to individualized therapy," said Stafford O'Kelly, head of Abbott's molecular diagnostics business, in a statement.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.